IGC Pharma Inc
SWB:IGS1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for IGC Pharma Inc.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What IGC Pharma Does
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The firm's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions.
- Headquarters
- United States of America US
- Employees
- 70
- IPO date
- Apr 13, 2006
Continue IGS1 Research
Decided on IGC Pharma? Get an email when IGS1 reaches the price you’d buy at. Free with an account.